A Novel BAFF / APRIL Dual Inhibitor in Treating Refractory Autoimmune Hepatitis

A subset of autoimmune hepatitis (AIH) patients fail to respond to standard treatments or experience frequent relapses. This study evaluates the efficacy and safety of telitacicept, a BAFF/APRIL dual inhibitor, as a rescue therapy. Two AIH patients treated with telitacicept were included. The first, steroid-dependent and refractory to multiple immunosuppressants, showed significant reductions in transaminases and immunoglobulin G, enabling steroid tapering. The second, with comorbid systemic lupus erythematosus, maintained remission and reduced steroid and mycophenolate mofetil doses. No severe adverse events were reported. Telitacicept shows promise as a safe therapy for refractory AIH.